Evidence map›Paper›PMID 41401466›Full record

ArticleThe Journal of international medical research2025

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Ke-Jun Liu, Tao Jiang, Quan-Quan Tan, Hua-Jun Chen, Qing Zhou, Xu-Chao Zhang, Zheng Zheng, Yi-Long Wu, Jun Jia, Jin-Ji Yang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ke-Jun LiuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.ORCID 0000-0003-1721-2723
Tao JiangSchool of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, China.
Quan-Quan TanGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.
Hua-Jun ChenGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.
Qing ZhouGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.
Xu-Chao ZhangGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.
Zheng ZhengSchool of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, China.
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.
Jun JiaDongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), China.
Jin-Ji YangGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundExon 20 insertions of epidermal growth factor receptor (EGFR) exhibit varying sensitivity to traditional and novel tyrosine kinase inhibitors for non-small cell lung cancer.MethodsMolecular dynamics simulations were used to investigate the structural dynamics of wild-type EGFR and three representative exon 20 insertion mutations: V769_D770insASV (ASV), D770_N771insSVD (SVD), and N773_insNPH (NPH). Furthermore, the binding mechanisms of osimertinib and mobocertinib were explored to understand their efficacy across different EGFR variants.ResultsIn this study, we found that binding to osimertinib and mobocertinib changed the free energy landscapes for ASV-, SVD- and NPH-

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsExonsLung NeoplasmsProtein Kinase InhibitorsAcrylamidesAniline CompoundsHumansIndolesMolecular Dynamics SimulationMutagenesis, InsertionalPyrimidinesTyrosine Kinase InhibitorsAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesTyrosine Kinase Inhibitorsepidermal growth factor receptorexon 20 insertionsmolecular dynamics simulationnon-small cell lung cancerTargeted therapy

Identifiers

PMID41401466
PMCPMC12709010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.